DOCSLIB.ORG

Croi2020-Program-And-Information

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Croi2020-Program-And-Information General Information CONTENTS Information General CROI FOUNDATION . 2 IAS–USA . 3 CONTINUING MEDICAL EDUCATION . 3 CROI 2020 PROGRAM COMMITTEE . 6 Scientific Program Committee . 6 Community Liaison Subcommittee . 8 EXTERNAL REVIEWERS . 9 SCHOLARSHIP AWARDEES . 11 Activities for New Investigator Awardees . 11 New Investigator Awardees . 11 International Investigator Awardees . 16 Community Educator Awardees . 16 CONFERENCE INFORMATION . 18 Overview . 18 Conference Support . 18 Conference Resources . .19. WiFi Access at the Conference . 19 Mobile App . 19 Poster Videos . 19 Website . 19 Webcasts . 19 USB Flashdrive . 20 Affiliated and Proximate Activities Policy . 20 Conference Badges . 20 Conference Etiquette . 20 VENUE Conference Services . 21 Meals . 22 Emergency Services . .22 Overflow Accommodations . 22 Americans With Disabilities Act . 22 Child Care . 22 CROI HOTELS . 23 ABSTRACT PROCESS . 25 Abstracts Related to Study Populations . 27 PRECONFERENCE SESSIONS . 28 SYMPOSIA, ORAL SESSIONS, AND THEMED DISCUSSIONS BY DAY . 34 POSTER SESSIONS BY DAY . 66 POSTER SESSIONS BY CATEGORY . 173. INDEX OF PRESENTING AUTHORS . .178 . CONFERENCE SCHEDULE . INSIDE BACK COVER CONVENTION CENTER FLOOR PLANS . BACK COVER Printed in the United States of America . © Copyright 2020 CROI Foundation/IAS–USA . All rights reserved . ISBN #978-1-7320053-2-7 CROI 2020 1 General Information CROI FOUNDATION The CROI Foundation is a 501(c)(3) not-for-profit professional organization that operates exclusively for the charitable and educational purpose of organizing, promoting, and presenting the annual Conference on Retroviruses and Opportunistic Infections (CROI) . General Information Information General Roles and Responsibilities of the CROI Foundation Volunteer Board of Directors • Works closely with the CROI Program Committee (CROI PC) and the CROI Organizer to accomplish the mission of CROI • Approves nominations for members of the CROI PC and the CROI PC Chair and Vice Chairs • Ensures that the CROI PC is responsible for the scientific program content of CROI • Enters into and oversees the partner agreement with the CROI Organizer • Has the sole and absolute discretion to veto any policies, procedures, or actions taken or proposed that would pose a substantial risk of preventing the Foundation at any time from qualifying or continuing to qualify as a 501(c)(3) organization or that might cause the loss of such qualification • Oversees the long-term financial and administrative integrity of CROI CROI Foundation Board of Directors Constance A. Benson, MD Kevin M. De Cock, MD President Centers for Disease Control and Prevention University of California San Diego Nairobi, Kenya San Diego, CA, United States Scott M. Hammer, MD John M. Coffin, PhD Columbia University Secretary-Treasurer New York, NY, United States Tufts University Boston, MA, United States Sharon L. Hillier, PhD University of Pittsburgh Elaine J. Abrams, MD Pittsburgh, PA, United States ICAP at Columbia University New York, NY, United States James A. Hoxie, MD University of Pennsylvania Susan P. Buchbinder, MD Philadelphia, PA, United States San Francisco Department of Public Health John W. Mellors, MD San Francisco, CA, United States University of Pittsburgh Pittsburgh, PA, United States Judith S. Currier, MD, MSc University of California Los Angeles Robert T. Schooley, MD Los Angeles, CA, United States University of California San Diego La Jolla, CA, United States 2 CROI 2020 General Information IAS–USA Information General The International Antiviral (formerly AIDS) Society–USA (IAS–USA) serves as the Conference Organizer for the logistical planning and organization for CROI in partnership with the CROI Foundation and Program Committee . The mission of the IAS–USA is to improve the prevention, treatment, care, and quality of life for people with or at risk of HIV or other viral infections and their associated health conditions through high-quality, relevant, balanced, and needs-oriented education and information for practitioners and scientists who are actively involved in medical care and research . To access primary educational and informational programs sponsored by the IAS–USA, please visit www .iasusa .org for: • Live CME courses and webinars available for signup • Archived webcasts of CME courses and webinars • Topics in Antiviral Medicine™, including the annual CROI review • Practice guidelines CONTINUING MEDICAL EDUCATION Accreditation Statement The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians . The IAS–USA designates this live activity for a maximum of 17.50 AMA PRA Category 1 Credits™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity . Objectives After participating in CROI 2020, participants will be able to: • Describe basic science research advances in HIV • List the most recent findings from clinical trials in the field of HIV and the implications of these data for state-of-the-art treatment strategies • Describe current epidemiologic data on the prevalence of HIV infection, transmission, treatment, and linkage to and retention in care in populations worldwide; the implications of these data for public-health program planning; and current advances in biobehavioral prevention Statement of Need Since HIV was identified, the scientific response to the global pandemic has been a coordinated effort among basic researchers, clinical investigators, health care providers, epidemiologists, and community leaders to move information and potential treatment options from research to clinical trials and out to affected communities as quickly as possible . CROI was founded in 1993, by researchers working in the field of HIV/AIDS and its complications, as a science-focused forum for exchanging current research findings among their international peers . CROI continues to focus on scientific exchange, providing an environment in which basic science researchers, translational researchers, clinical investigators, epidemiologists, and public health experts meet to present and discuss the latest research into different facets of HIV and its complications, as well as selected other emerging infections . CROI 2020 3 General Information CME Credit Information Physicians (MD, DO, and international equivalents) are eligible to receive CME credit for participation in CROI . CME credits can be claimed for premeeting workshops, opening session lectures, plenary lectures, and symposia . CME credits cannot be claimed for oral abstract sessions, themed discussion sessions, or poster sessions . For physician attendees certified by the American Board of Internal Medicine (ABIM), Maintenance of Certification (MOC) points are available for participation General Information Information General in CROI . Other researchers, practitioners, and attendees can receive a Certificate of Participation verifying their attendance, as required by the American Medical Association (AMA) . ABIM MOC Points Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 17.50 MOC points in the ABIM MOC program . Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity . It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit . Claiming CME Credits, ABIM MOC Points, or a Certificate of Participation During the conference, links to the daily and final evaluations will be available in your CROI profile on the CROI or IAS-USA website . Detailed instructions will be provided . You will need the email address that you used to register for this conference and your reference number (on your badge) to access this page . To obtain CME credits, ABIM MOC points, or a Certificate of Participation for CROI, all final evaluations and claim forms must be submitted by April 11, 2020 . Once the final evaluation and posttest are submitted, your certificate will be uploaded to your CROI profile on the CROI or IAS–USA website . To determine the number of CME credits, ABIM MOC points, or hours of participation that can be claimed, calculate time spent attending the conference activities, including premeeting workshops, opening session lectures, plenary lectures, and symposia . For example, if you attended 2 plenary talks (8:30 AM to 9:30 AM), and a symposium (4:00 PM to 6:00 PM), you would have a total of 3 hours to apply toward CME credits or ABIM MOC points (if applicable) for that day . At the end of CROI, please add the total hours you attended . A CME/ABIM MOC hour worksheet can be found at www .CROIconference .org/sites/ default/files/uploads/croi2020-cme-worksheet .pdf . Disclosure of Financial Relationships It is the policy of the IAS–USA to ensure balance, independence, objectivity, and scientific rigor in all its educational activities . All faculty members (planners, speakers, presenters, etc) participating in IAS–USA-sponsored activities are required to disclose to the program audience any financial relationships with commercial interests within the past 12 months that could be perceived to influence, or give the appearance of potentially influencing, the written or oral presentation . The ACCME defines financial relationships as “those relationships in which the individual benefits by receiving a salary, royalty, intellectual
Load more

Recommended publications
  • Race Breakdown
    Race Breakdown Event Date Track Fast Qualifier First Second Third 1 4/26/1997 Anderson Speedway (IN) Biff George Brian Ross Bill Baird J.R. Roahrig 2 5/4/1997 Salem Speedway (IN) Brian Ross Kenny Tweedy Brian Rievley J.R. Roahrig 3 6/20/1997 Lucas Oil Raceway (IN) Kenny Tweedy Kenny Tweedy J.R. Roahrig Josh Clemons 4 7/18/1997 Lucas Oil Raceway (IN) Kenny Tweedy Brian Ross Chet Fillip Jim Crabtree Jr. 5 8/15/1997 Anderson Speedway (IN) Ray Skillman Brian Ross Brian Rievley Kenny Tweedy 6 9/1/1997 Winchester Speedway (IN) Todd Oliver Brian Rievley Kenny Tweedy Rick Turner 7 9/20/1997 Anderson Speedway (IN) Brian Ross Brian Ross Kenny Tweedy Chet Fillip 8 10/12/1997 Salem Speedway (IN) Kenny Tweedy Chet Fillip Ray Skillman Royce Mason 9 4/25/1998 Anderson Speedway (IN) Kenny Tweedy Ken Weaver Bobby Blount Brian Rievley 10 5/3/1998 Salem Speedway (IN) Ken Weaver Kenny Tweedy Brian Rievley Brian Ross 11 5/16/1998 Anderson Speedway (IN) Jim Cooper Jim Cooper Bobby Blount Matt Hagans 12 6/7/1998 Salem Speedway (IN) Brian Ross Dave Jackson Matt Hagans Tony Johnson 13 6/13/1998 Anderson Speedway (IN) Ray Skillman Jim Cooper Scott Neal Bobby Blount 14 6/27/1998 Winchester Speedway (IN) Chet Fillip Chet Fillip Scott Neal Kenny Tweedy 15 7/5/1998 Salem Speedway (IN) Ray Skillman Jim Cooper Matt Hagans Scott Neal 16 7/11/1998 Angola Motorsport Speedway (IN) Larry Zent Bobby Blount Scott Hantz Brian Rievley 17 8/1/1998 Anderson Speedway (IN) Jim Crabtree Jr.
    [Show full text]
  • Pre-Existing and De Novo Humoral Immunity to SARS-Cov-2 in Humans
    bioRxiv preprint doi: https://doi.org/10.1101/2020.05.14.095414; this version posted July 23, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Pre-existing and de novo humoral immunity to SARS-CoV-2 in humans Kevin W. Ng1*, Nikhil Faulkner1*, Georgina H. Cornish1*, Annachiara Rosa2*, Ruth Harvey3, Saira Hussain3, Rachel Ulferts9, Christopher Earl4, Antoni Wrobel5, Donald Benton5, Chloe Roustan6, William Bolland1, Rachael Thompson1, Ana Agua-Doce7, Philip Hobson7, Judith Heaney13, Hannah Rickman13, Stavroula Paraskevopoulou13, Catherine F. Houlihan13,14, Kirsty Thomson13, Emilie Sanchez13, 0David Brealey13, Gee Yen Shin13, Moira J. Spyer13,15, Dhira Joshi8, Nicola O'Reilly8, Philip A .Walker6, Svend Kjaer6, Andrew Riddell7, Catherine Moore16, Bethany R. Jebson17,19, Meredyth G.Ll. Wilkinson17,19, Lucy R. Marshall17,19, Elizabeth C. Rosser17,18, Anna Radziszewska17,18, Hannah Peckham17,18, Coziana Ciurtin17,18, Lucy R. Wedderburn17,19, Rupert Beale9, Charles Swanton10, Sonia Gandhi11, Brigitta Stockinger12, John McCauley3, Steve Gamblin5, Laura E. McCoy12†, Peter Cherepanov2†, Eleni Nastouli13,15† and George Kassiotis1,20† 1Retroviral Immunology; 2Chromatin structure and mobile DNA Laboratory; 3Worldwide Influenza Centre; 4Signalling and Structural Biology Laboratory; 5Structural Biology of Disease Processes Laboratory; 6Structural Biology STP; 7Flow
    [Show full text]
  • National News in ‘09: Obama, Marriage & More Angie It Was a Year of Setbacks and Progress
    THE VOICE OF CHICAGO’S GAY, LESBIAN, BI AND TRANS COMMUNITY SINCE 1985 Dec. 30, 2009 • vol 25 no 13 www.WindyCityMediaGroup.com Joe.My.God page 4 LGBT Films of 2009 page 16 A variety of events and people shook up the local and national LGBT landscapes in 2009, including (clockwise from top) the National Equality March, President Barack Obama, a national kiss-in (including one in Chicago’s Grant Park), Scarlet’s comeback, a tribute to murder victim Jorge Steven Lopez Mercado and Carrie Prejean. Kiss-in photo by Tracy Baim; Mercado photo by Hal Baim; and Prejean photo by Rex Wockner National news in ‘09: Obama, marriage & more Angie It was a year of setbacks and progress. (Look at Joining in: Openly lesbian law professor Ali- form for America’s Security and Prosperity Act of page 17 the issue of marriage equality alone, with deni- son J. Nathan was appointed as one of 14 at- 2009—failed to include gays and lesbians. Stone als in California, New York and Maine, but ad- torneys to serve as counsel to President Obama Out of Focus: Conservative evangelical leader vances in Iowa, New Hampshire and Vermont.) in the White House. Over the year, Obama would James Dobson resigned as chairman of anti-gay Here is the list of national LGBT highlights and appoint dozens of gay and lesbian individuals to organization Focus on the Family. Dobson con- lowlights for 2009: various positions in his administration, includ- tinues to host the organization’s radio program, Making history: Barack Obama was sworn in ing Jeffrey Crowley, who heads the White House write a monthly newsletter and speak out on as the United States’ 44th president, becom- Office of National AIDS Policy, and John Berry, moral issues.
    [Show full text]
  • August 13-14, 2015 Fred Hutchinson Cancer Research Center Seattle, Washington Cgt4hivcure2015.Org COMMUNITY EVENT
    August 13-14, 2015 Fred Hutchinson Cancer Research Center Seattle, Washington cgt4hivcure2015.org COMMUNITY EVENT Seattle, August 13-14 TABLE OF CONTENTS Welcome........................................................................................ 2 Scholarship Recipients .............................................................4 Scientific Organizing Committee ......................................... 5 Agenda ........................................................................................... 6 Keynote .......................................................................................... 8 Plenary Speakers ...................................................................... 10 Speakers (by session) ..............................................................14 Poster Presentation Abstracts ............................................43 Host Organizations ..................................................................58 Dinner and Reception .............................................................62 Sponsors ..................................................................................... 64 Community Representation and Financial Support .. 68 Conference on Cell & Gene Therapy for HIV Cure 2015 1 WELCOME On behalf of the Scientific Organizing Committee, we are pleased to welcome you to the 2nd annual Conference on Cell & Gene Therapy for HIV Cure 2015. It is a privilege to host this year’s event and we are proud to showcase the cutting-edge research in cell and gene therapy that has brought us closer than
    [Show full text]
  • CAPITULO 01.Indd
    DRUG RESISTANCE: 1. DEFINITIONS AND CONCEPTS • José Ramón Santos • Marc Noguera-Julian • Maria Casadellà • Josep Maria Llibre • Bonaventura Clotet • Roger Paredes 1.1. INTRODUCTION Definition Antiretroviral drug resistance is the ability of HIV to replicate in the presence of antiretroviral drug concentrations that suppress viral replication of non-resistant virus. Most antiretroviral drugs are competitive inhibitors, i.e. they inhibit a viral enzyme (protease, PR; reverse transcriptase, RT; integrase, IN) by competing with its natural substrate for attachment to the enzyme’s catalytic site. Resistance to competitive inhibitors is a function of viral susceptibility and the drug levels achieved in the target cells. Higher drug levels can suppress partially resistant viruses, with resistance occurring in a continuum. Viral susceptibility to competitive inhibitors is expressed as the drug concentration able to inhibit virus growth in vitro to 50% (50% inhibitory concentration, 1 IC50) or 90% (IC90), relative to a wildtype reference virus. The small-molecule CCR5 antagonists, are allosteric inhibitors of the human CCR5 transmembrane protein, one of the two co-receptors required for HIV entry into target cells. Due to their allosteric inhibition, decrease in viral susceptibility to CCR5 antagonists is reflected by progressive decreases in the percent of maximal inhibition rather than by shifts in IC50. Further increases in drug concentrations once drug resistance is established do not achieve further virological suppression. Pathogenesis HIV has a quasispecies distribution.1 Soon after infection with a relatively homogeneous viral population, viral replication ensues at an extraordinary rate: 109-12 new virions are generated every day. Because HIV’s RT lacks proofreading ability, 10-3 to 10-4 mutations (one or two per genome) are spontaneously generated per replication cycle.2, 3 Given HIV’s high replication rate, any single mutant and some dual mutants could be generated per day.
    [Show full text]
  • Contentious Corporate Social Responsibility Practices by British American Tobacco in Cameroon
    CONTENTIOUS CORPORATE SOCIAL RESPONSIBILITY PRACTICES BY BRITISH AMERICAN TOBACCO IN CAMEROON Práticas contenciosas de responsabilidade social corporativa pela British American Tobacco nos Camarões Kingsly Awang Ollong1 Introduction Increasingly consumers, employees and managers expect companies, particularly large multinationals, to go beyond their traditional role of creating, producing, packaging and selling—for a profit. Public opinion opines that job creation and tax paying no longer suffice as private sector’s sole contribution to society. The existence of tobacco and cigarette companies triggers the question of the reasonableness of CSR activities undertaken by the companies. While it is known that cigarettes have a negative impact on human health in particular, the act of tobacco companies that is by undertaking CSR has invited a huge controversy which is seen as a platform to maintain its operations. The common denominator among the vast majority of ethical or socially responsible investment policies and products is the exclusion of tobacco companies in their portfolios (Yack et al., 2001:191). Well-planned and well-managed philanthropy, from sponsoring music, film and art festivals to creating education programs for the disadvantaged to protecting the environment, in the name of corporate social responsibility (CSR) has become a necessary element in virtually every large corporation’s business plan. Many businesses from a wide range of sectors conduct projects and programmes that aim to reduce social inequity—by creating or improving health care or educational facilities, providing vocational and management training, enhancing the quality of leisure and cultural activities. Specific sectors are recognizing their responsibilities and orient their CSR efforts to areas especially relevant to their business.
    [Show full text]
  • Collection Overview
    Archives Collections Guide Updated March 28, 2016 Collection Overview The Gerber/Hart archives focuses its collections on gay, lesbian, bisexual, transgender, and queer life in the Chicago metropolitan area and the Midwest. It contains over 150 collections of historically significant personal manuscripts, photographs, audiovisual recordings, and organizational records. These collections include unpublished material such as letters, diaries, and scrapbooks documenting the lives of both average people and community leaders. They also include the records of many community organizations, businesses, and political campaigns. This guide is intended to serve as a preliminary research tool that provides a brief description of holdings with basic information on size, inclusive dates, types of records, and broad subject areas. Guide Contents List of Collections..............................................................................................................................................2 Collections Descriptions....................................................................................................................................6 Name Index......................................................................................................................................................26 Topical Index...................................................................................................................................................34 1 Archives Collections Guide Updated March 28, 2016 List of Collections
    [Show full text]
  • Risk Factors, Symptom Reporting, Healthcare-­Seeking Behaviour and Adherence to Public Health Guidance: Protocol for Virus Watch, a Prospective Community Cohort Study
    BMJ Open: first published as 10.1136/bmjopen-2020-048042 on 23 June 2021. Downloaded from Open access Protocol Risk factors, symptom reporting, healthcare- seeking behaviour and adherence to public health guidance: protocol for Virus Watch, a prospective community cohort study Andrew Hayward,1 Ellen Fragaszy,2,3 Jana Kovar,1 Vincent Nguyen,1,2 Sarah Beale,1,2 Thomas Byrne,2 Anna Aryee,2 Pia Hardelid ,4 Linda Wijlaars ,5,6 Wing Lam Erica Fong,2 Cyril Geismar,1,2 Parth Patel,2 Madhumita Shrotri,2 Annalan M D Navaratnam,1,2 Eleni Nastouli,5,7 Moira Spyer,5,7 Ben Killingley,8,9 Ingemar Cox,10 Vasileios Lampos,10 Rachel A McKendry,11 Yunzhe Liu,12 Tao Cheng,12 Anne M Johnson,13 Susan Michie,14 Jo Gibbs,13 Richard Gilson,13 Alison Rodger,13,15 Robert W Aldridge 2 To cite: Hayward A, Fragaszy E, ABSTRACT Strengths and limitations of this study Kovar J, et al. Risk factors, Introduction The coronavirus (COVID-19) pandemic has symptom reporting, healthcare- caused significant global mortality and impacted lives around ► Virus Watch is a large national household com- seeking behaviour and the world. Virus Watch aims to provide evidence on which adherence to public health munity cohort study of the occurrence of and risk public health approaches are most likely to be effective guidance: protocol for Virus factors for COVID-19 infection that aims to recruit in reducing transmission and impact of the virus, and will Watch, a prospective community 50 000 people, including 12 500 from minority eth- investigate community incidence, symptom profiles and cohort study.
    [Show full text]
  • 1 CO-OPERATION AGREEMENT Dated As of 27 September 2010
    CO-OPERATION AGREEMENT dated as of 27 September 2010 among IMPERIAL TOBACCO LIMITED AND THE EUROPEAN UNION REPRESENTED BY THE EUROPEAN COMMISSION AND EACH MEMBER STATE LISTED ON THE SIGNATURE PAGES HERETO 1 ARTICLE 1 DEFINITIONS Section 1.1. Definitions........................................................................................... 7 ARTICLE 2 ITL’S SALES AND DISTRIBUTION COMPLIANCE PRACTICES Section 2.1. ITL Policies and Code of Conduct.................................................... 12 Section 2.2. Certification of Compliance.............................................................. 12 Section 2.3 Acquisition of Other Tobacco Companies and New Manufacturing Facilities. .......................................................................................... 14 Section 2.4 Subsequent changes to Affiliates of ITL............................................ 14 ARTICLE 3 ANTI-CONTRABAND AND ANTI-COUNTERFEIT INITIATIVES Section 3.1. Anti-Contraband and Anti-Counterfeit Initiatives............................ 14 Section 3.2. Support for Anti-Contraband and Anti-Counterfeit Initiatives......... 14 ARTICLE 4 PAYMENTS TO SUPPORT THE ANTI-CONTRABAND AND ANTI-COUNTERFEIT COOPERATION ARTICLE 5 NOTIFICATION AND INSPECTION OF CONTRABAND AND COUNTERFEIT SEIZURES Section 5.1. Notice of Seizure. .............................................................................. 15 Section 5.2. Inspection of Seizures. ...................................................................... 16 Section 5.3. Determination of Seizures................................................................
    [Show full text]
  • Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2
    Abstract Book Towards an HIV Cure Symposium, 2013 Towards an HIV Cure Symposium 2013 Abstract Book 2 Contents Oral Abstract Session 1 4 OA1-1 4 OA1-2 5 OA1-3 6 OA1-4 LB 7 OA1-5 LB 8 Oral Abstract Session 2 9 OA2-1 9 OA2-2 10 OA2-3 11 OA2-4 12 OA2-5 LB 13 OA2-6 LB 14 OA2-7 LB 15 Oral Abstract Session 3 16 OA3-1 16 OA3-2 17 OA3-3 18 OA3-4 LB 19 Oral Abstract Session 4 20 OA4-1 20 OA4-2 22 OA4-3 LB 24 OA4-4 LB 25 Poster Exhibition 26 A5 – Entry (attachment, receptors and co-receptors, penetration and tropism) 26 A8 – Regulation of viral gene expression and replication 27 A9 – Cellular factors necessary for HIV replication 28 A10 – Cellular and tissue reservoirs 31 A11 – Mechanisms of HIV persistence 36 A13 – Strategies to target and eradicate reservoirs 37 A14 – Mucosal transmission 43 A19 – Intrinsic cellular defenses and restriction factors 44 A20 – IFN-I (viral inhibition, immunomodulatory functions) 46 Back to Content page Towards an HIV Cure Symposium 2013 Abstract Book 3 A21 – NK cells and dendritic cells 47 A22 – Monocytes and macrophages 49 A24 – Antibody diversity and function 51 A27 – Cellular immunity 53 A28 – Mucosal immunity 56 A29 – Viral determinants of pathogenesis 57 A30 – Acute and early HIV/SIV infection 58 A41 – Elite controllers 59 A44 – Highly exposed seronegative individuals (HESN) 61 A45 – Correlates of protection 62 A46 – HIV drug development 63 A47 – Mechanisms of anti-retroviral drug resistance 65 A49 – Nucleic acid based HIV and SIV therapy development 67 A50 – Design of approaches targeting inflammation/immune
    [Show full text]
  • Arizona State University Commencement and Convocation Program
    TE TA UN S E ST TH AT I F E V A O O E L F A DITAT DEUS N A E R R S I O Z T S O A N Z E I A R I T G R Y A 1912 1885 ARIZONA STATE UNIVERSITY COMMENCEMENT AND CONVOCATION PROGRAM Spring 2015 May 11–16, 2015 THE NATIONAL ANTHEM THE STAR SPANGLED BANNER O say can you see, by the dawn’s early light, What so proudly we hailed at the twilight’s last gleaming? Whose broad stripes and bright stars through the perilous fight O’er the ramparts we watched, were so gallantly streaming? And the rockets’ red glare, the bombs bursting in air Gave proof through the night that our flag was still there. O say does that Star-Spangled Banner yet wave O’er the land of the free and the home of the brave? ALMA MATER ARIZONA STATE UNIVERSITY Where the bold saguaros Raise their arms on high, Praying strength for brave tomorrows From the western sky; Where eternal mountains Kneel at sunset’s gate, Here we hail thee, Alma Mater, Arizona State. —Hopkins-Dresskell MAROON AND GOLD Fight, Devils down the field Fight with your might and don’t ever yield Long may our colors outshine all others Echo from the buttes, Give em’ hell Devils! Cheer, cheer for A-S-U! Fight for the old Maroon For it’s Hail! Hail! The gang’s all here And it’s onward to victory! Students whose names appear in this program are candidates for the degrees listed, which will be conferred subject to completion of requirements.
    [Show full text]
  • The Euresist Approach for Predicting Response to Anti HIV-1 Therapy!
    97! www.geno2pheno.org www.euresist.org The EuResist approach for predicting response to anti HIV-1 therapy! Andre Altmann1, Michal Rosen-Zvi2, Mattia Prosperi3, Ehud Aharoni2, Hani Neuvirth2, Eugen Schülter4, Joachim Büch1, Yardena Peres2, Francesca Incardona5, Anders Sönnerborg6, Rolf Kaiser4, Maurizio Zazzi7, Thomas Lengauer1 1 Max Planck Institute for Informatics, Saarbrücken, Germany; 2 IBM Research Laboratory in Haifa, Haifa, Israel; 3 University of Roma TRE, Rome, Italy; 4 University of Cologne, Cologne, Germany; 5 Informa srl, Rome, Italy; 6 Department of Medicine, Karolinksa Institute, Stockholm, Sweden; 7 University of Siena, Siena, Italy _____________________________________________________________ Background ____________________________________________________________ The aims of the EuResist project are integration of clinical and virologic data from a large cohort of patients and training of a data-driven therapy response prediction system for guiding treatment selection using these data. The EuResist Integrated Database (EIDB) currently comprises 18,467 patients, 22,006 sequences, 64,864 therapies, and 240,795 viral load (VL) measurements collected from Italy, Sweden, Germany, and Luxembourg. _______________________________________________________________ Methods______________________________________________________________ Therapy success (failure) is defined as a VL measurement below (above) 500 cp/ml at 8 [4-12] weeks after therapy start. Baseline VL and genotype must be obtained at most three months before therapy start to allow for inclusion in the training set. Using this Standard Datum definition we extracted 3,023 samples for training three different prediction engines. The engines were designed to work with viral genotype and intended regimen as the only information (minimal feature set) as well as with additional measurements (e.g. baseline VL) and information derived from previous treatments and genotypes (maximal feature set) to enhance prediction performance.
    [Show full text]